BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form 8-K — Jul 30, 2026
$BCLIForm 8-KItems 5.02, 7.01, 9.01Filed Jul 30, 2026, 4:30 PM ET0001104659-26-088728Original filing
Brainstorm Cell Therapeutics Inc. appointed Peter Pitts, a current board member, as Executive Chairman and Chief Strategic Regulatory Officer effective July 24, 2026. He received a stock option grant to purchase 900,000 shares and will forgo a base salary or cash bonus, receiving compensation primarily through equity. Former Chairman Jacob Frenkel resigned from the Board on the same date but will transition to an advisory role to assist with the transition.
Key figures
- Frenkel rsu shares
- 100000
- Pitts stock option shares
- 900000
- Pitts option exercise price
- $1.00
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.